Relay Therapeutics, Inc.RLAYEarnings & Financial Report
Nasdaq
RLAY Q3 2025 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-80.4M
Net Profit
$-74.1M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-0.43
Relay Therapeutics, Inc. Q3 2025 Financial Summary
Relay Therapeutics, Inc. reported revenue of $0 for Q3 2025, with a net profit of $-74.1M (N/A margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-74.1M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q3 2025 |
Relay Therapeutics, Inc. Annual Revenue by Year
Relay Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $10.0M).
| Year | Annual Revenue |
|---|---|
| 2024 | $10.0M |
| 2023 | $25.5M |
| 2022 | $1.4M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $-1000 | $10.0M | $0 | $0 | $0 | $7.7M | $677000 | $0 |
| YoY Growth | -100.4% | 4327.9% | N/A | N/A | N/A | -23.3% | N/A | N/A |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $844.0M | $841.4M | $772.5M | $930.1M | $871.3M | $799.4M | $728.8M | $670.0M |
| Liabilities | $92.0M | $95.7M | $90.8M | $91.3M | $93.5M | $78.3M | $63.2M | $62.3M |
| Equity | $752.0M | $745.8M | $681.7M | $838.9M | $777.8M | $721.1M | $665.7M | $607.7M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-89.2M | $-50.3M | $-65.8M | $-75.1M | $-57.9M | $-73.2M | $-55.3M | $-62.1M |